Clinical trial
Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
NCT00330252 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Weekly Subcutaneous Alemtuzumab and Rituximab for Relapsed CLL
- Lead sponsor
- Dana-Farber Cancer Institute
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- May 31, 2006
- Completion date
- January 31, 2014
- Enrollment
- 29 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
chronic lymphocytic leukemia